Navigation Links
AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
Date:3/6/2009

ificant long-term revenue for the Company while building value for our shareholders," said Juergen Engel, Ph.D., President and CEO of AEterna Zentaris.

About the Phase 3 Program with Cetrorelix in BPH

Cetrorelix pamoate is currently in three Phase 3 trials involving more than 1,600 patients with symptomatic BPH in Canada, the United States and Europe.

The first multi-center efficacy study for which patient recruitment was completed in April 2008, is currently being conducted primarily in the United States and Canada, with additional sites in Europe and involves 667 patients under the supervision of lead investigator, Herbert Lepor, MD, Professor at NYU School of Medicine, New York. Patients enter a 4-week run-in no-treatment observation period to confirm severity and stability of voiding symptoms based on the International Prostate Symptom Score (IPSS). Patients are then randomly allocated to cetrorelix or placebo in a double-blind fashion. Patients are administered cetrorelix by intra-muscular (IM) injection at Week 0, 2, 26 and 28 and are followed up to Week 52. Then, in an open-label extension, patients receive cetrorelix by IM injection at Week 52, 54, 78 and 80 and are followed up to Week 90.

The second multi-center Phase 3 efficacy study for which patient recruitment was completed in October 2008, involves 420 patients, mainly in Europe. Patients in this randomized placebo-controlled study with open-label extension conducted under the supervision of lead investigator, Prof. Frans M.J. Debruyne, MD, of the Andros Mannenkliniek, Arnhem, The Netherlands, receive cetrorelix according to similar dosing regimens used in the first study.

The primary endpoint for both North American and European efficacy studies is absolute change in IPSS between baseline and Week 52. Other efficacy endpoints include additional measures of BPH symptom progression and the need for BPH-related surgery. Safety endpoints include ch
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. AEterna Zentaris to Present at Upcoming RBC Capital Markets Healthcare Conference
2. AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
3. AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results
4. AEterna Zentaris to Announce Third Quarter 2008 Financial and Operating Results on November 13, 2008
5. AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
6. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
7. AEterna Zentaris to Present at Upcoming Oppenheimer 19th Annual Healthcare Conference
8. AEterna Zentaris Receives Notification from Nasdaq Relating to Minimum Bid Price
9. AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
10. AEterna Zentaris to Present at BioContact Quebec on October 2, 2008
11. AEterna Zentaris to Present at Upcoming CIBC World Markets 7th Annual Eastern Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 26, 2014 Publicis Healthcare Communications Group ... the organization has won a total of 20 awards ... LifeBrands was honored with a Silver Award and 11 ... eight Awards of Excellence. , The Annual Rx ... and promotion. The Awards provide a forum for the ...
(Date:11/26/2014)... November 26, 2014 The North ... segments the market for detailed analysis of the ... market to reach $616.3 million by 2018, growing ... 2018. , Browse through the TOC of the ... get an idea of the in-depth analysis and ...
(Date:11/26/2014)... , Nov. 26, 2014 Space is ... exploration of space requires astronauts to maintain consistently high ... success, and prevent potential errors and accidents. Despite the ... known about how cognition is affected by prolonged spaceflight, ... Now, Penn Medicine researchers are poised to help ...
(Date:11/26/2014)... The ETC (Emerging Technology Centers) http://www.etcbaltimore.com ... today that applications for AccelerateBaltimore™ (AB) 2015 program ... have a big idea?,” asked ETC’s President Deb ... it. AccelerateBaltimore helps you and your big idea ... weeks.” Interested game changers with “big ideas” ...
Breaking Biology Technology:Publicis Healthcare Wins 20 Rx Club Awards 2Publicis Healthcare Wins 20 Rx Club Awards 3The North America Thermal Protective Clothing Market is estimated to grow up to $616.3 million by 2018 - Report by MicroMarket Monitor 2The North America Thermal Protective Clothing Market is estimated to grow up to $616.3 million by 2018 - Report by MicroMarket Monitor 3Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 2Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 3Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 4AccelerateBaltimore Applications to Close in 6 Days 2AccelerateBaltimore Applications to Close in 6 Days 3
... /Xinhua-PRNewswire-FirstCall/ -- China,Biologic Products, Inc. (OTC Bulletin ... of the leading plasma-based pharmaceutical companies in ... guidance following,the recently announced acquisitions which will ... of plasma based products in China., ...
... AMES, Iowa, Oct. 16 Advanced Analytical Technologies,Inc. (AATI), ... production space,adding an additional 1200 ft2 of space to ... company occupies in Building 4 on the,ISU Research Park ... company will continue to occupy space in 2 building ...
... Radiation Therapy Trials to US ... Patients for First Time, HOUSTON, Oct. 16 The ... they have entered into a,collaboration to increase patient access to ... setting., The collaboration means patients receiving cancer care at ...
Cached Biology Technology:China Biologic Products Provides Preliminary Guidance for 2009 of Revenues of $90 to $100 Million and Net Income of $18 to 22 Million 2China Biologic Products Provides Preliminary Guidance for 2009 of Revenues of $90 to $100 Million and Net Income of $18 to 22 Million 3Advanced Analytical Technologies, Inc. Expands Into New Office and Production Space 2Radiation Therapy Oncology Group and US Oncology Enter Collaboration to Increase Patient Access to National Clinical Trials 2Radiation Therapy Oncology Group and US Oncology Enter Collaboration to Increase Patient Access to National Clinical Trials 3Radiation Therapy Oncology Group and US Oncology Enter Collaboration to Increase Patient Access to National Clinical Trials 4Radiation Therapy Oncology Group and US Oncology Enter Collaboration to Increase Patient Access to National Clinical Trials 5
(Date:11/4/2014)... , Nov. 4, 2014   Neurotechnology ... today announced that the latest version of its ... the Ongoing MINEX evaluation organized by ... fingerprint algorithms using the INCITS 378 fingerprint standard ... requirement in public tenders in the ...
(Date:11/3/2014)... A University of Colorado Cancer Center study ... Academy of Sciences describes the activity of a ... Interleukin 37 or IL-37. It has been known to ... in the adaptive immune system: IL-37 inhibits the ability ... antigens. , "Knowing this mechanism that underlies IL-37,s effect ...
(Date:11/3/2014)... birth weight and preterm birth are linked to increased ... published in the American College of Rheumatology (ACR) journal, ... birth weight and pre-term babies were not at greater ... , According to the ACR, 27 million Americans ... OA. Symptoms of OA range from mild to severe ...
Breaking Biology News(10 mins):Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3PNAS: From HIV to cancer, IL-37 regulates immune system 2Preterm, low birth-weight babies may need new hips in adulthood 2
... A University of Oklahoma-led study has demonstrated that ancient ... The microbiomes from ancient people have broad reaching implications ... what good bacteria might have been lost as a ... aseptic practices. Cecil M. Lewis Jr., professor of ...
... cell is like a small city, with factoriescalled organellesdedicated ... functions. A network of intercellular "highways," called microtubules, enables ... about the cell to keep this vital machinery humming. ... Proceedings of the National Academy of Sciences sheds ...
... researchers from across the Asia-Pacific gathered today for the ... Osteoporosis Meeting, taking place at the Kuala Lumpur Convention ... Minister of Health of Malaysia, YB Datuk Rosnah bt. ... than 60 nations. His Excellency Tun Dato, Seri Utama ...
Cached Biology News:OU study suggests the bacterial ecology that lives on humans has changed in the last 100 years 2Study sheds light on how cells transport materials along crowded intercellular 'highways' 2Study sheds light on how cells transport materials along crowded intercellular 'highways' 3IOF Asia-Pacific Meeting presents new research and advances in osteoporosis management 2IOF Asia-Pacific Meeting presents new research and advances in osteoporosis management 3
... Luminescent Detection System is intended for use ... generated by an in-house validated method for ... selected target of interest. • ... is a hybridization capture assay designed to ...
... culture scale-up, these culture chambers produce cell ... 9 range and are useful alternatives ... • High mechanical • strength and structural ... shipping • Certified nonpyrogenic and sterilized by ...
Mouse monoclonal [7B9] to beta II Tubulin ( Abpromise for all tested applications). Antigen: Synthetic peptide, CEEEEGEDEA found at the c-terminus of beta II tubulin. Entrez GeneID: 10383 ...
...
Biology Products: